|Day's Range||0.0600 - 0.0600|
Yahoo Finance's Dan Roberts, Sibile Marcellus, and Julia La Roche discuss Amgen's falling stock after it's key lung cancer drug missed Wall Street forecasts.
THOUSAND OAKS, Calif. , Sept. 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference at 9:45 a.m. British Summer Time on Wednesday, ...
THOUSAND OAKS, Calif., Sept. 13, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab) (KdD) compared to KYPROLIS and dexamethasone alone (Kd) met its primary endpoint of progression-free survival (PFS).
Shares of Amgen are on an upswing after winning a patent battle over its drug Enbrel against Novartis subsidiary Sandoz. Is it time to buy shares of the massive biotech company?
Jaclyn Schuler’s role as a leader at Amgen in Tampa is to motivate her teams to deliver value and impact the bottom line.
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
THOUSAND OAKS, Calif., Sept. 12, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that new data from its oncology portfolio and pipeline will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019. Data featured from Amgen's hematology franchise will include oral presentations from Phase 1 studies of AMG 420, the anti-B-cell maturation antigen (BCMA) bispecific T cell engager (BiTE®) and AMG 176, the MCL-1 inhibitor in patients with relapsed or refractory multiple myeloma. Other data being presented will include safety and efficacy results of once-weekly dosing of KYPROLIS® (carfilzomib) in different regimens across several patient populations, and Phase 3 results from the first KYPROLIS trial to be conducted in China.
REYKJAVIK, Iceland , Sept. 11, 2019 /CNW/ -- deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants. The project will allow the complete sequencing of the genetic code of all 500,000 participants in the UK Biobank. The UK Biobank is an extraordinary resource for medical research that Great Britain has built over the past 15 years.
Shares of pharmaceutical companies toppled Tuesday on reports the House of Representatives will release a plan that allows the federal government to negotiate drug prices in Medicare.
Alexion (ALXN) strengthens its amyloidosis portfolio with an exclusive license secured from Eidos to develop and commercialize an investigational small molecule AG10 in Japan.
Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.
Horizon (HZNP) announces the FDA has accepted the Biologics License Application (BLA) for teprotumumab, for the treatment of active thyroid eye disease, and granted it Priority Review designation.
Amgen stock toppled Monday after the biotech company's experimental cancer treatment failed to impress investors in a Phase 1 study. The drug attempts to inhibit a protein known as KRAS.
Microsoft Corp and Amgen Inc were among the biggest drags on the S&P 500 and Nasdaq. Amgen fell 3.19% after analysts raised questions about data on the company's lung cancer drug, dragging the healthcare sector down 0.94%. Financial stocks rose 1.20%, providing the biggest boost to the S&P 500, with banks gaining 2.62%.
Amgen said in a Sunday statement that new data from the Phase 1 study of AMG 510 presented as an oral presentation at the IASLC 2019 World Conference on Lung Cancer, or WCLC, showed that out of the 13 of the evaluable patients receiving the target dose of 960mg once daily — the highest dose — seven, or 54%, achieved a partial response at one or more timepoints and six achieved stable disease. Nine of the 13 patients are continuing to take the daily pill, Amgen said. Of the partial responders, two died and another quit the study due to disease progression.